Myungmoon Pharm starts to sell ‘Creon’ under co-promotion agreement with Abott Korea
Myungmoon Pharm will sell ‘Creon,’ a Abott Korea’s pancreatic enzyme replacement therapy(PERT).
Myungmoon Pharm(CEO Seok-Min Woo, Chun-Shik Park) and Aboot Korea(CEO Seung-Yoon Lee) recently signed a co-promotion agreement of ‘Creon,’ a PERT that is effective on pancreatic exocrine disorder.
Un...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
